Raia Drogasil (Raia Drogasil) Interest Expense : $-149 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Raia Drogasil Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Raia Drogasil's interest expense for the three months ended in Mar. 2024 was $ -43 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-149 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Raia Drogasil's Operating Income for the three months ended in Mar. 2024 was $ 105 Mil. Raia Drogasil's Interest Expense for the three months ended in Mar. 2024 was $ -43 Mil. Raia Drogasil's Interest Coverage for the quarter that ended in Mar. 2024 was 2.44. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Raia Drogasil Interest Expense Historical Data

The historical data trend for Raia Drogasil's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raia Drogasil Interest Expense Chart

Raia Drogasil Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-67.90

-51.10

-50.66

-97.60

-141.15

Raia Drogasil Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-35.86	-35.16	-33.97	-36.49	-43.19

Raia Drogasil Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-149 Mil.

Raia Drogasil (OTCPK:RADLY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Raia Drogasil's Interest Expense for the three months ended in Mar. 2024 was $-43 Mil. Its Operating Income for the three months ended in Mar. 2024 was $105 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $1,155 Mil.

Raia Drogasil's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Mar. 2024 )	/	Interest Expense (Q: Mar. 2024 )
	=	-1	*	105.435	/	-43.187
	=	2.44

The higher the ratio, the stronger the company's financial strength is.

Raia Drogasil (Raia Drogasil) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Raia Drogasil SA (OTCPK:RADLY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

RADL3:Brazil

Address

Avenue Corifeu de Azevedo Marques, 3097 Butanta, Sao Paulo, SP, BRA, 05339-9000

Website

https://ri.rd.com.br

Raia Drogasil SA is a large retail drug store operator in Brazil. The company's stores sell branded and generic medication, over-the-counter medicine, health and beauty aids, perfumery, cosmetics, household items, and personal care products. The company also acts as a pharmacy benefit manager, performing medical purchases with prenegotiated discounts. The majority of Raia Drogasil's revenue is generated through branded drug sales, while the bulk of the remaining revenue stems from perfumery, over-the-counter drugs, and generic drugs. The company owns a variety of stakes in operational subsidiaries.